VX 135

Drug Profile

VX 135

Alternative Names: ALS-002200; ALS-2200; VX-135

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Bristol-Myers Squibb; Vertex Pharmaceuticals
  • Class Antivirals; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 May 2014 Vertex Pharmaceuticals and Bristol-Myers Squibb complete a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand (NCT01842451)
  • 01 May 2014 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in France and Romania (PO)
  • 01 May 2014 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA, Moldova and New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top